China Medical Device Imports Remain Stable in H1 2025

China’s medical device import market demonstrated continued stability in the first half of 2025, even as structural adjustments became more visible across product categories and source countries. According to customs data, total imports reached RMB 167.793 billion (≈ USD 24 billion), representing a year-on-year decline of approximately 1%. This modest movement points to consolidation rather than a systemic slowdown.

While headline figures suggest continuity, closer examination of category-level and geographic data highlights evolving demand patterns that remain highly relevant for overseas manufacturers.

Category Performance Highlights Diverging Import Trends

While China’s medical device import picture remains largely consistent with previous patterns, select segments are undergoing measured rebalancing as clinical needs and procurement priorities evolve.

Key category outcomes include:

In vitro diagnostic (IVD) reagents remained firmly in first place, with imports totalling RMB 61.365 billion (≈ USD 8.713 billion), up 3.64% year-on-year
Medical consumables totaled RMB 50.620 billion (≈ USD 7.188 billion), declining slightly by 1.82% year-on-year
Diagnostic and therapeutic equipment recorded imports of RMB 36.849 billion (≈ USD 5.232 billion), a 3.23% increase year-on-year
IVD instruments followed a different trajectory, with imports of RMB 14.230 billion (≈ USD 2.020 billion), down 8.42% year-on-year

Within medical imaging, demand patterns became increasingly differentiated. Imports of ultrasound equipment surged by 528.25%, reflecting sustained investment in flexible and non-invasive technologies. At the same time, imports of certain mature technologies — including image intensifiers and dental X-ray equipment — declined by 60.52% and 49.68%, respectively.

Import Sources Show Gradual Diversification

Shifts were also visible in the geographic composition of China’s medical device imports, suggesting a steady diversification of supply rather than reliance on a narrow group of source countries.

In H1 2025, Europe accounted for about 49.66% of China’s medical device imports, making it the largest source region. Countries such as Germany and Switzerland contributed significantly to this share, underscoring Europe’s strong technological and trade advantages in the sector.

The three largest source countries — the United States, Germany, and Switzerland — together represented 48.8% of total imports:

United States: RMB 39.3 billion (≈ USD 5.6 billion), representing 23.4% of total imports
Germany: RMB 28.2 billion (≈ USD 4.0 billion), representing 16.8% of total imports
Switzerland: RMB 14.2 billion (≈ USD 2.0 billion), representing 8.5% of total imports

At the same time, imports from Mexico and France increased their combined presence in the market. Mexico and France accounted for 5.11% and 2.62% of total import value, respectively, with year-on-year growth of 13.1% and 4.8%. This trend points to incremental diversification and expanding opportunities for secondary sourcing countries with competitive and differentiated product offerings.

China’s Domestic Regional Distribution

Medical device imports remain highly concentrated in China’s economically developed coastal regions, where healthcare infrastructure is more advanced and demand for advanced medical technologies remains strongest.

In H1 2025, Shanghai, Beijing, Jiangsu, and Guangdong ranked as the top four regions by import value, together accounting for 89.3% of total imports and maintaining a substantial lead over other provinces. Shanghai alone accounted for more than half of national import volume over the past year, reflecting its role as a preferred hub for multinational medical device companies’ China operations.

Regional trends show:

Beijing, Shanghai, and Jiangsu continued to increase their import shares
Guangdong has seen a slight decline, possibly related to development in the local medical device industry and foreign brand factory expansion

This regional disparity reflects differences in medical resource distribution and industrial policy across China.

Strategic Implications for Overseas Manufacturers

China’s import data continues to reflect the combined influence of industrial policy, centralized procurement, clinical demand, and global supply chain dynamics. While certain segments are adjusting, the overall environment remains conducive to well-positioned foreign manufacturers.

Key strategic considerations include:

Sustained opportunities in IVD reagents and select diagnostic technologies, particularly where technical complexity limits domestic substitution
Competition in mature equipment categories reinforces the importance of differentiation and value-based positioning
Strong alignment between import demand and advanced, clinically essential technologies with clear performance or regulatory advantages over domestic alternatives

Careful calibration of product portfolios and market strategies remains essential as China’s medical device market continues its gradual evolution.

Final Thoughts

Although forecasting short-term movement in China’s medical device market can be complex, recent import data provides a clear and constructive signal. Stability in core segments such as medical consumables, combined with targeted growth in areas like IVD reagents and advanced imaging, highlights where demand remains resilient. When assessed alongside regulatory and policy developments, these trends offer overseas manufacturers a practical basis for refining market strategy, prioritizing investment, and identifying sustainable opportunities in China’s evolving healthcare landscape.